Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report

BACKGROUND: As a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib is the standard treatment for patients with EGFR mutations. Diarrhea and rash are the most common side effects, and some rare adverse reactions have started appearing owing to their i...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Li, You, Liu, Yu, Zhao, Zichen, Zhang, Yan
Aineistotyyppi: Online Artikkeli Teksti
Kieli:English
Julkaistu: AME Publishing Company 2023
Aiheet:
Case Report
Linkit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087996/
https://www.ncbi.nlm.nih.gov/pubmed/37057122
http://dx.doi.org/10.21037/tlcr-22-916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087996/
https://www.ncbi.nlm.nih.gov/pubmed/37057122
http://dx.doi.org/10.21037/tlcr-22-916

Samankaltaisia teoksia